Extracellular DNA and F-actin as targets in antibiofilm cystic fibrosis therapy

Future Microbiology

Volumn 4, Issue 6, 2009, Pages 645-647

  Tolker Nielsen, Tim ^a   Høiby, Niels ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBONUCLEASE; DNA; F ACTIN; POLYASPARTIC ACID; POLYGLUTAMIC ACID; TOBRAMYCIN;

ARTICLE; BACTERIAL COLONIZATION; BIOFILM; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

PSEUDOMONAS AERUGINOSA;

EID: 69849083858     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.09.38     Document Type: Article

References (13)

1. Parks QM, Young RL, Poch KR, Malcolm KC, Vasil ML, Nick JA: Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapy. J. Med. Microbiol. 58(4), 492-502 (2009).
2. Walker TS, Tomlin KL, Worthen GS et al.: Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect. Immun. 73(6), 3693-3701 (2005).
3. Tang JX, Janmey PA: The polyelectrolyte nature of F-actin and the mechanism of actin bundle formation. J. Biol. Chem. 271(15), 8556-8563 (1996).
4. Tang JX, Wen Q, Bennett A et al.: Anionic poly(amino acid)s dissolve F-actin and DNA bundles, enhance DNase activity, and reduce the viscosity of cystic fibrosis sputum. Am. J. Physiol. Lung Cell. Mol. Physiol. 289(4), L599-L605 (2005).
5. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS: Extracellular DNA required for bacterial biofilm formation. Science. 295(5559), 1487 (2002).
6. Allesen-Holm M, Barken KB, Yang L et al.: A characterization of DNA release in Pseudomonas aeruginosa cultures and biofilms. Mol. Microbiol. 59(4), 1114-1128 (2006).
7. Bjarnsholt T, Jensen PØ, Fiandaca MJ et al.: Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr. Pulmonol. 44(6), 547-558 (2009).
8. Worlitzsch D, Tarran R, Ulrich M et al.: Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest. 109(3), 317-325 (2002).
9. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL: Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am. Rev. Resp. Dis. 132, 761-765 (1985).
10. Goldstein W, Döring G: Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis. Am. Rev. Respir. Dis. 134, 49-56 (1986).
11. -/-mice. Antimicrob. Agents Chemother. 51, 3677-3687 (2007).
12. Pressler T, Frederiksen B, Skov M, Garrad P, Koch C, Høiby N: Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection - a case control study. J. Cystic Fibrosis 5, 9-15 (2006).
13. Hansen CR, Pressler T, Høiby N: Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J. Cystic Fibrosis 7, 523-530 (2008).